SCHEMBL1960948

SCHEMBL1960948

FC(F)(F)Oc1ccc(Cn2ccc3nc(-c4ccccc4)nc-3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.41
HCRTR1 O43613 2/20 0.40
HCRTR2 O43614 2/20 0.40
CACNA1G O43497 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNA1I Q9P0X4 1/20 0.40
CHRM5 P08912 3/20 0.40
HPGDS O60760 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
BCHE P06276 2/20 0.39
ACHE P22303 2/20 0.39
BACE1 P56817 2/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13481750 0.85 KCNH2 (0.53) SCN5AHCRTR1HCRTR2CACNA1GCACNA1H
SCHEMBL1961673 0.84 CYP11B1 (0.49) HPGDSALDH1A1KDM4ENPC1MAPT
SCHEMBL1959703 0.84 KCNH2 (0.44) HPGDSNPC1MAPTRAB9ACYP11B1
SCHEMBL1961068 0.83 CYP11B1 (0.50) HPGDSALDH1A1NPC1GAARAB9A
SCHEMBL1411948 0.83 HPGDS (0.54) HPGDSALDH1A1GAAMAPTRAB9A
Hydrochloric Acid SCHEMBL2344066 0.82 KCNH2 (0.44) HPGDSNPC1MAPTRAB9ACYP11B1
SCHEMBL1959676 0.82 CYP11B1 (0.47) HPGDSALDH1A1KDM4ENPC1MAPT
SCHEMBL3191494 0.81 KCNH2 (0.45) SCN5AHCRTR1HCRTR2CHRM5ALDH1A1
SCHEMBL1958116 0.80 SMN1; SMN2 (0.50) HPGDSALDH1A1NPC1MAPTRAB9A
SCHEMBL13463717 0.80 KCNH2 (0.43) SCN5AHCRTR1HCRTR2CHRM5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2332938-B1 Viral inhibitors LEUVEN K U RES & DEV (BE) 2014-10-01 EP disclosed
US-8779141-B2 Viral inhibitors GILEAD SCIENCES, INC. (US) 2014-07-15 US disclosed
EP-1521754-B1 VIRAL INHIBITORS LEUVEN K U RES & DEV (BE) 2011-08-31 EP disclosed
EP-2332938-A1 Viral inhibitors K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2011-06-15 EP disclosed
US-7737162-B2 Viral inhibitors GILEAD SCIENCES, INC. (US) 2010-06-15 US disclosed
US-20100004281-A1 VIRAL INHIBITORS GILEAD SCIENCES, INC. 2010-01-07 US disclosed
US-20050239821-A1 Viral inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2005-10-27 US disclosed
EP-1521754-A2 VIRAL INHIBITORS K.U.Leuven Research & Development (BE) 2005-04-13 EP disclosed
WO-2004005286-A2 VIRAL INHIBITORS K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004281-A1 VIRAL INHIBITORS ZC3HAV1, MAVS, HAVCR2 SCN5A 1251/4885HCRTR1 4274/4885HCRTR2 4719/4885
US-20050239821-A1 Viral inhibitors ZC3HAV1, ZC3HAV1L, ACE SCN5A 1411/4885HCRTR1 4140/4885HCRTR2 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.